Milestone Scientific Expands Adoption of CompuFlo® Epidural System with Commercial Rollout at Pain Doctors Medical LLC
MWN-AI** Summary
Milestone Scientific Inc. (NYSE: MLSS), known for its innovative drug delivery instruments, has initiated the commercial rollout of its CompuFlo® Epidural System at Pain Doctors Medical LLC, a specialized interventional pain management center located in Roseland, NJ. This follows a successful evaluation led by Dr. Ilana Etelzon, a board-certified expert in Interventional Pain Management, who has integrated the system into her practice, aiming to enhance patient safety and procedural efficiency.
The CompuFlo® Epidural System utilizes Milestone's proprietary Dynamic Pressure Sensing Technology® to verify epidural needle placement in real time. This technological advancement enhances the accuracy of pain management procedures and minimizes potential complications, providing reassurance to both medical professionals and patients. Dr. Etelzon praised the system for its capability to provide immediate feedback during epidural procedures, which significantly improves procedural accuracy and efficacy.
The commercial launch coincides with recent Medicare price assignments for the CompuFlo® System, promoting broader accessibility within interventional pain management and rehabilitation settings. The system’s clinical validation is establishing it as an essential tool in improving patient care.
Neal Goldman, Chairman and Interim CEO of Milestone Scientific, emphasized that the partnership with Pain Doctors Medical LLC marks a strategic approach to expanding the reach of their CompuFlo® technology. With increasing reimbursement coverage, the company anticipates accelerated growth in this sector.
Milestone Scientific Inc. continues to focus on developing cutting-edge injection technologies aimed at enhancing the precision, efficiency, and overall safety of medical procedures. As they navigate the regulatory landscape and market demands, they remain committed to supporting healthcare providers in delivering superior patient care.
MWN-AI** Analysis
Milestone Scientific Inc. (NYSE: MLSS) is poised for significant growth, especially following the recent commercial rollout of its CompuFlo® Epidural System at Pain Doctors Medical LLC. This innovative system enhances patient safety and assures procedural accuracy through real-time feedback on epidural needle placement. The integration of such cutting-edge technology in leading interventional pain management centers indicates a pivotal shift in pain management practices, which could have far-reaching implications for Milestone's market performance.
The positive endorsement from Dr. Ilana Etelzon signals strong clinical confidence, and as the system gains traction, it appears likely to enhance Milestone's market share in a competitive industry. Additionally, the recent Medicare price assignment for the CompuFlo® Epidural System presents a unique opportunity for expanded accessibility, aligning with growing demand for efficient pain management solutions. As reimbursement structures strengthen, the potential for broader adoption of this technology could lead to increased revenue streams for Milestone.
For investors, the strategic focus on expanding partnerships within interventional pain management centers is promising. This vertical integration not only bolsters Milestone’s product visibility but also cements its reputation as a leader in safe and effective injection technology.
However, prospective investors should remain mindful of the inherent risks associated with healthcare technology companies, including regulatory hurdles, competitive pressures, and the necessity for sustained innovation. It would be prudent to monitor Milestone’s quarterly earnings reports and updates on product adoption rates, ensuring alignment with broader market trends and reimbursement policies.
In conclusion, Milestone Scientific, backed by clinical validation and expanding market reach, represents a compelling investment opportunity. Continuous analysis of operational performance and industry developments will be crucial as the company navigates its growth trajectory in the medical technology landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ROSELAND, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the commercial implementation of its CompuFlo® Epidural System at Pain Doctors Medical LLC, a specialized interventional pain management center. This rollout follows a successful evaluation led by Dr. Ilana Etelzon, MD, a board-certified expert in Interventional Pain Management and Physical Medicine & Rehabilitation Medicine, who has integrated the technology into her practice to enhance patient safety and procedural efficiency.
The CompuFlo® Epidural System uses Milestone Scientific’s proprietary Dynamic Pressure Sensing Technology® to provide real-time verification of epidural needle placement. This precision-driven approach improves safety and reduces the risk of complications, allowing for greater confidence in pain management procedures.
Dr. Etelzon commented, “The CompuFlo® Epidural System represents a significant advancement in epidural administration. The ability to confirm needle placement with real-time feedback not only enhances procedural accuracy but also provides peace of mind for both physicians and patients. Integrating this technology into my practice at Pain Doctors Medical LLC allows us to deliver safer and more effective pain management solutions.”
This launch follows the recent Medicare price assignment for the CompuFlo® Epidural System, which is helping drive broader accessibility across interventional pain management and rehabilitation centers. With a strong track record of clinical validation, the system is increasingly being recognized as an essential tool for improving patient care.
Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, added, “Expanding our reach within interventional pain management centers like Pain Doctors Medical LLC is a crucial step in broadening the reach of our CompuFlo® technology. Dr. Etelzon’s positive experience with the system reaffirms its clinical benefits, and we are committed to furthering its adoption across leading pain management providers. As reimbursement coverage continues to strengthen, we anticipate accelerating growth within this sector.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology ® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com .
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2023 . The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
FAQ**
How does the recent commercial implementation of Milestone Scientific Inc. (MLSS)'s CompuFlo® Epidural System at Pain Doctors Medical LLC enhance patient safety in interventional pain management?
What factors contributed to the successful evaluation of the CompuFlo® Epidural System led by Dr. Ilana Etelzon, MD, and how might this impact Milestone Scientific Inc. (MLSS)'s reputation in the medical community?
With the recent Medicare price assignment, how is Milestone Scientific Inc. (MLSS) planning to further expand the accessibility of the CompuFlo® Epidural System to other pain management centers?
What challenges could Milestone Scientific Inc. (MLSS) face as it seeks to accelerate growth in the interventional pain management sector, based on the current market conditions?
**MWN-AI FAQ is based on asking OpenAI questions about Milestone Scientific Inc. (NYSE: MLSS).
NASDAQ: MLSS
MLSS Trading
5.09% G/L:
$0.2952 Last:
18,932 Volume:
$0.2816 Open:
